Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
Two-Drug Combo Supercharges Liver Cancer Therapy in Preclinical Study
Two-Drug Combo Supercharges Liver Cancer Therapy in Preclinical Study
Read also
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs
BMO Capital Markets favors Merck’s pipeline strategy to offset the Keytruda patent cliff over Bristol Myers Squibb's efforts to replace Opdivo and Eliquis.
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
Sanofi and Regeneron are expanding their immunology collaboration in a deal worth up to $8 billion to co-develop four new long-acting antibodies.
Bristol Myers Squibb secures expanded US approval for Camzyos
The US FDA has expanded the approval of Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in adolescents.
Teva Presents Post Hoc Ecopipam Data Ahead of 2027 FDA Decision
Teva presents post hoc ecopipam data at a medical congress ahead of the FDA's anticipated Q1 2027 decision for pediatric Tourette syndrome treatment.
